NRG-BN006 Clinical Trial
Participation in a clinical trial is one possible option for people who have cancer. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.
NRG-BN006, is a Phase 2/3 trial for the treatment of patients with newly diagnosed glioblastoma. Enrollment is expected to begin in the second half of 2019 and will be conducted by NRG Oncology under its NCI-funded grant. The trial is designed to assess the benefit of adding Toca 511 & Toca FC to chemotherapy and radiation compared to standard of care alone.
Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.